drugset / Trial / NCT00308100

Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

NCT00308100

Phase 4 Terminated 53 enrolled Fresenius Kabi
RandomizedParallel-groupOpen-labelTreatment

Summary

There are no standardized plasma volume replacement protocols during liver transplantation surgery. The current study is designed to compare efficacy, safety, and costs of perioperative volume replacement with Voluven (Hydroxyethyl starch 130/0.4) and albumin in patients undergoing liver transplantation.

Timeline

Start
2005-10
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Albumin Protein / enzyme biologic
Subject Volulyte Other / unclassified 33 unknown

Indications

No indication recorded.